Another big-seller, the hypertension medication Avapro, saw sales climbed 7% to $328 million . That product, whose key patent expires in 2012, ...
"Valuation now better reflects the company's growth challenges beyond Plavix, Avapro, and Abilify," Kelly wrote in a client note. ...
"Last week I had a patient call and ask to be changed from Avapro to Benicar because it was a few dollars cheaper," he said. ...
'Valuation now better reflects the company's growth challenges beyond Plavix, Avapro, and Abilify,' Kelly wrote in a client note. ...
"The patent cliff in 2012, which includes Plavix, (hypertension treatment) Avapro and returning (bipolar drug) Abilify to Otsuka create a significant hurdle ...
... has substantial research capability and the two groups have been historic partners in the marketing of Plavix and blood pressure treatment Avapro. ...
Patel also suggested Bristol might even want to get out of its co-marketing arrangement with Sanofi-Aventis for the anti-hypertension drug Avapro. ...
... of blood pressure treatment avapro rose 12 percent to $309 million, while sales of colon cancer drug erbitux grew 6 percent to $185 million. continued. ...
Now with Avapro (irbesartan) and Avalide physicians have more therapeutic options to treat mild, moderate and severe hypertension."
Our sales forecasts for (hypertension drug) Avapro were increased by $20 million-$200 million during 2007-2010. There were no changes to our Avapro sales ...